Zevra (ZVRA) news
Recent news
Zevra Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Aug 21, 2026Zevra Therapeutics Q2 EPS USD 0.14
AInvest Wire · Aug 5, 2026Zevra Therapeutics Inc: BTIG cuts target price to $24 from $27
AInvest Wire · Jul 27, 2026Zevra Therapeutics Inc: Canaccord Genuity cuts target price to $20 from $29
Canaccord Genuity has revised its price target for Zevra Therapeutics Inc (NASDAQ: ZEVR), lowering it to $20 from a previous $29, according to a recent analyst note. The adjustment reflects a reassessment of the company’s near-term prospects and market conditions. The firm continues to monitor the…
AInvest Wire · Jul 27, 2026Zevra Therapeutics shares down 24.5% after EU panel adopts negative opinion on co's rare disease drug application
Zevra Therapeutics Inc. (NASDAQ: ZEVR) experienced a significant decline in its stock price, falling 24.5% following a negative opinion issued by an European Union regulatory panel regarding the company’s application for a rare disease drug. The panel’s decision raises uncertainty about the drug’s…
AInvest Wire · Jul 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.